Real-World Strategies for the Management of Narcolepsy: Highlights from the 2021 Sleep Meeting on Dosing and Titration

CMEO Snack

Premiere Date: Monday, August 30, 2021

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Tuesday, August 30, 2022

Begin Activity Now

Faculty


Richard K. Bogan, MD, FCCP, FAASM
Richard K. Bogan, MD, FCCP, FAASM 
President of Bogan Sleep Consultants, LLC
Associate Clinical Professor
University of South School of Medicine
Columbia, SC
Associate Clinical Professor
Medical University of South Carolina
Charleston, SC

Michael J. Thorpy, MD
Michael J. Thorpy, MD 
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
Bronx, NY
President, New York State Society of Sleep Medicine
Past President of the Sleep Section, Academy of Neurology

Statement of Need

Narcolepsy is a devastating neurological condition characterized by excessive daytime sleepiness (EDS). It carries a high degree of disability, comorbidity, and burden. While stimulants are typically regarded as first-line therapies for EDS, they are often associated with efficacy, safety, and tolerability issues. Non-stimulants have emerged as demonstrating considerable safety as well as efficacy in a variety of domains beyond mere improved EDS, but also psychosocial functioning, work performance, and driving. However, developing safe, effective treatment regimens, particularly as it pertains to treatment initiation and modification, may be challenging.

This CME Outfitters Snack will provide clinicians with the latest evidence on real-world strategies for dosing and titrating pharmacotherapies for the management of narcolepsy.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Apply updates from recent clinical trials on optimal strategies to dose and titrate pharmacotherapies for the management of narcolepsy.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care physicians, PAs, nurse practitioners, and pharmacists

Credit Information

Jointly Accredited Provider
JA

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Physicians (ACCME):
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC):
This activity is designated for .5 contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Pharmacists (ACPE):
This knowledge-based activity is approved for .5 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-21-021-H01-P).

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Royal College MOC:Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals, U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Dr. Thorpy reports that he is a consultant or on the advisory board for Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Limited; Takeda Pharmaceutical Company Limited; and XWPharma.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

SN-148-083021-43